BIAFW Stock Price, Chart, Stats & News
bioAffinity Technologies, Inc. (BIAFW) does not currently pay a dividend.
BIAFW chart
Fundamentals
Gross margin | 23.21% |
Operating margin | -171.58% |
Pretax margin | -241.25% |
Net margin | -241.96% |
Effective tax rate | -0.30% |
ROA | -136.03% |
ROE | -385.19% |
D/E | 0.16x |
Interest coverage ratio | -238.27x |
BIAFW valuation
P/E | 0.38x |
P/S | 2.92x |
P/B | 0.95x |
P/CF | -0.74x |
P/FCF | -1.93x |
P/OCF | -0.74x |
PEG | -0.02x |
EV multiple | -1.62x |
About
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Similar securities
Based on sector and market capitalization
